Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 23 (oversold) · MACD above its signal · 4% above its 52-week low
| 6.88 | 52-week high | +804.91% |
| 2.46 | Previous month high | +223.56% |
| 1.02 | Previous month low | +34.16% |
| 0.8890 | Previous week high | +16.93% |
| 0.8251 | R3 (classic) | +8.52% |
| 0.8001 | R2 (classic) | +5.23% |
| 0.7802 | R1 (classic) | +2.62% |
| 0.7751 | Previous day high | +1.95% |
| 0.7603 | Price now | |
| 0.7552 | Pivot | −0.67% |
| 0.7500 | Previous week low | −1.35% |
| 0.7353 | S1 (classic) | −3.29% |
| 0.7302 | Previous day low | −3.96% |
| 0.7300 | 52-week low | −3.99% |
| 0.7103 | S2 (classic) | −6.58% |
| 0.6904 | S3 (classic) | −9.19% |
None of the 29 investors followed here reported a position in CMPX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CMPX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 28, 2026 | Lerner Neil LOfficer | Purchase at price 1.89 per share. | 15K | $28.35K |
| Apr 28, 2026 | Anderman JonathanGeneral Counsel | Purchase at price 1.89 per share. | 25K | $47.25K |
| Apr 28, 2026 | Lerner Neil LOfficer | Stock Award(Grant) at price 1.89 per share. | 15K | $28.35K |
| Apr 28, 2026 | Anderman JonathanGeneral Counsel | Stock Award(Grant) at price 1.89 per share. | 25K | $47.25K |
| Jan 1, 2026 | Lerner Neil LOfficer | Stock Award(Grant) at price 5.17 per share. | 62.5K | $323.13K |
| Jan 1, 2026 | Schuetz Thomas J.Chief Executive Officer | Stock Award(Grant) at price 5.17 per share. | 250K | $1.29M |
| Jan 1, 2026 | Shin BarryChief Financial Officer | Stock Award(Grant) at price 5.17 per share. | 125K | $646.25K |
| Jan 1, 2026 | Anderman JonathanGeneral Counsel | Stock Award(Grant) at price 5.17 per share. | 150K | $775.50K |
| May 26, 2025 | Schuetz Thomas J.Chief Executive Officer | Purchase at price 2.11 per share. | 10K | $21.10K |
| Apr 6, 2025 | Lerner Neil LOfficer | Purchase at price 1.42 per share. | 20K | $28.40K |
| Apr 6, 2025 | Anderman JonathanGeneral Counsel | Purchase at price 1.54 per share. | 20K | $30.80K |
| Dec 8, 2024 | Shin BarryChief Financial Officer | Stock Award(Grant) at price 1.65 per share. | 400K | $660.00K |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 19.2 | -11.7 | -6.4 | -66.5 | 34.5 | -8.0 | -12.8 | 25.1 | -56.5 | -26.9 | −85.8% | ||
| 2025 | 122.1 | -9.9 | -34.5 | -2.1 | 12.9 | 23.8 | 14.2 | 17.5 | 0.3 | 6.9 | 55.1 | -7.4 | +270.3% |
| 2024 | -16.7 | 36.9 | 11.2 | -27.3 | -2.1 | -29.1 | 3.0 | 53.4 | 16.5 | -10.9 | -0.6 | -11.0 | −7.1% |
| 2023 | -20.5 | -5.3 | -13.7 | -8.0 | -3.7 | 9.7 | -9.7 | -18.8 | -15.5 | -8.6 | -8.3 | -5.5 | −69.0% |
| 2022 | -44.8 | 16.0 | -32.5 | 8.0 | 106.1 | -13.1 | -1.9 | 5.8 | -17.1 | 38.6 | 30.1 | 22.4 | +58.7% |
| 2021 | -40.0 | 13.1 | 3.2 | -28.6 | -2.6 | -11.4 | 5.0 | 0.0 | −54.7% |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Buy / hold / sell counts